Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRONULIFE Effenergy is a probiotic combination product developed by Glac Biotech, consisting of two specific bacterial strains: *Lactococcus lactis* subsp. *lactis* LY-66 and *Lactobacillus plantarum* PL-02. These strains were originally isolated from an Olympic weightlifting gold medalist and are marketed as a dietary supplement to enhance exercise performance, explosive strength, and endurance. The product works by modulating the gut microbiota, which in turn improves fatty acid metabolism, increases glycogen storage in the liver and muscles, and reduces exercise-induced inflammation and muscle damage. Clinical research has also investigated its efficacy in supporting weight loss and metabolic health in individuals with obesity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactococcus lactis subsp. lactis LY-66 + lactobacillus plantarum PL-02.